Page last updated: 2024-12-08

pentalenene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

pentalenene: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11009055
CHEBI ID17251
MeSH IDM0083088

Synonyms (11)

Synonym
(1r,3as,5as,8ar)-1,2,3,3a,5a,6,7,8-octahydro-1,4,7,7-tetramethylcyclopenta[c]pentalene
(1alpha,3a alpha,5a beta,8ar*)-1,2,3,3a,5a,6,7,8-octahydro-1,4,7,7-tetramethylcyclopenta(c)pentalene
(1r,3as,5as,8ar)-1,4,7,7-tetramethyl-1,2,3,3a,5a,6,7,8-octahydrocyclopenta[c]pentalene
CHEBI:17251
(+)-pentalenene
73306-73-7
pentalenene
cyclopenta[c]pentalene
(1r,2r,5s,8s)-2,6,10,10-tetramethyltricyclo[6.3.0.01,5]undec-6-ene
Q27102286
DTXSID101126804

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" For example, compound 51 had a good PK profile in both dog and monkey, and exhibited excellent efficacy when dosed orally in an inflammation model in hCCR2 KI mice."( Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.
Cai, C; Hou, C; Johnson, D; Kang, FA; McKenney, S; O'Neill, JC; Opas, E; Sui, Z, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
sesquiterpeneA C15 terpene.
ortho-fused tricyclic hydrocarbon
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (10.53)18.7374
1990's1 (5.26)18.2507
2000's6 (31.58)29.6817
2010's7 (36.84)24.3611
2020's3 (15.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]